Maitri Shah1, Zalak Karena1, Sangita V Patel2, Niyati Parmar2, Pawan K Singh3, Atul Sharma3. 1. Department of Obstetrics & Gynecology, Government Medical College, Baroda, Gujarat, India. 2. Department of Community Medicine, Government Medical College, Baroda, Gujarat, India. 3. Pfizer India Ltd. Patel Estate, Jogeshwari (East), Mumbai, India.
Abstract
OBJECTIVES: To measure the effect of vaginal estrogen cream in the treatment of vaginal atrophy in menopausal Indian women. METHODS: A total of 50 menopausal women aged between 40 and 80 years old with symptoms of vaginal atrophy were selected and treated with 0.5 g vaginal estrogen cream, twice weekly for 12 weeks. The women were followed-up monthly where symptom score, Genital Health Clinical Evaluation (GHCE) score, vaginal pH, and vaginal maturation index (VMI) were assessed and compared to baseline data. Any adverse events were recorded. RESULTS: There was a significant improvement (p < 0.010) in complaints such as vaginal dryness, itching, burning, and dyspareunia at the end of the study period. The clinical improvement of these patients was reflected in a decrease in GHCE score on every visit. Vaginal pH and VMI score also showed statistically significant improvements (p < 0.010). No side effects with the drugs used were recorded during the study period. CONCLUSIONS: Vaginal estrogen cream causes symptomatic relief in women of menopausal age in India suffering from vaginal atrophy.
OBJECTIVES: To measure the effect of vaginal estrogen cream in the treatment of vaginal atrophy in menopausal Indian women. METHODS: A total of 50 menopausal women aged between 40 and 80 years old with symptoms of vaginal atrophy were selected and treated with 0.5 g vaginal estrogen cream, twice weekly for 12 weeks. The women were followed-up monthly where symptom score, Genital Health Clinical Evaluation (GHCE) score, vaginal pH, and vaginal maturation index (VMI) were assessed and compared to baseline data. Any adverse events were recorded. RESULTS: There was a significant improvement (p < 0.010) in complaints such as vaginal dryness, itching, burning, and dyspareunia at the end of the study period. The clinical improvement of these patients was reflected in a decrease in GHCE score on every visit. Vaginal pH and VMI score also showed statistically significant improvements (p < 0.010). No side effects with the drugs used were recorded during the study period. CONCLUSIONS: Vaginal estrogen cream causes symptomatic relief in women of menopausal age in India suffering from vaginal atrophy.
Entities:
Keywords:
Atrophy; Estrogens, Conjugated; Postmenopause; Vaginal Cream; Women